Farquhar Michelle J, Harris Helen J, Diskar Mandy, Jones Sarah, Mee Christopher J, Nielsen Søren U, Brimacombe Claire L, Molina Sonia, Toms Geoffrey L, Maurel Patrick, Howl John, Herberg Friedrich W, van Ijzendoorn Sven C D, Balfe Peter, McKeating Jane A
Division of Immunity and Infection, Hepatitis C Research Group, University of Birmingham, Birmingham, United Kingdom.
J Virol. 2008 Sep;82(17):8797-811. doi: 10.1128/JVI.00592-08. Epub 2008 Jun 25.
Viruses exploit signaling pathways to their advantage during multiple stages of their life cycle. We demonstrate a role for protein kinase A (PKA) in the hepatitis C virus (HCV) life cycle. The inhibition of PKA with H89, cyclic AMP (cAMP) antagonists, or the protein kinase inhibitor peptide reduced HCV entry into Huh-7.5 hepatoma cells. Bioluminescence resonance energy transfer methodology allowed us to investigate the PKA isoform specificity of the cAMP antagonists in Huh-7.5 cells, suggesting a role for PKA type II in HCV internalization. Since viral entry is dependent on the host cell expression of CD81, scavenger receptor BI, and claudin-1 (CLDN1), we studied the role of PKA in regulating viral receptor localization by confocal imaging and fluorescence resonance energy transfer (FRET) analysis. Inhibiting PKA activity in Huh-7.5 cells induced a reorganization of CLDN1 from the plasma membrane to an intracellular vesicular location(s) and disrupted FRET between CLDN1 and CD81, demonstrating the importance of CLDN1 expression at the plasma membrane for viral receptor activity. Inhibiting PKA activity in Huh-7.5 cells reduced the infectivity of extracellular virus without modulating the level of cell-free HCV RNA, suggesting that particle secretion was not affected but that specific infectivity was reduced. Viral particles released from H89-treated cells displayed the same range of buoyant densities as did those from control cells, suggesting that viral protein association with lipoproteins is not regulated by PKA. HCV infection of Huh-7.5 cells increased cAMP levels and phosphorylated PKA substrates, supporting a model where infection activates PKA in a cAMP-dependent manner to promote virus release and transmission.
病毒在其生命周期的多个阶段利用信号通路为自身谋利。我们证明了蛋白激酶A(PKA)在丙型肝炎病毒(HCV)生命周期中的作用。用H89、环磷酸腺苷(cAMP)拮抗剂或蛋白激酶抑制剂肽抑制PKA可减少HCV进入Huh-7.5肝癌细胞。生物发光共振能量转移方法使我们能够研究Huh-7.5细胞中cAMP拮抗剂的PKA亚型特异性,提示II型PKA在HCV内化中发挥作用。由于病毒进入依赖于宿主细胞中CD81、清道夫受体BI和紧密连接蛋白1(CLDN1)的表达,我们通过共聚焦成像和荧光共振能量转移(FRET)分析研究了PKA在调节病毒受体定位中的作用。抑制Huh-7.5细胞中的PKA活性会导致CLDN1从质膜重新分布到细胞内囊泡位置,并破坏CLDN1与CD81之间的FRET,这表明质膜上CLDN1的表达对病毒受体活性很重要。抑制Huh-7.5细胞中的PKA活性可降低细胞外病毒的感染性,而不调节无细胞HCV RNA的水平,这表明颗粒分泌未受影响,但特异性感染性降低。从H89处理的细胞中释放的病毒颗粒与对照细胞释放的病毒颗粒具有相同范围的浮力密度,这表明病毒蛋白与脂蛋白的结合不受PKA调节。Huh-7.5细胞的HCV感染会增加cAMP水平并使PKA底物磷酸化,支持了一种模型,即感染以cAMP依赖的方式激活PKA以促进病毒释放和传播。